All blog posts
Total 277 results for
Showing 12 out of 277 results
14 May 2026
HSFKramer creates a comparative guide to the enforcement of trade secrets for IAM: China, the EU, UK and USA
27 April 2026
The EU Pharma Package is finally here – here's the settled position on key areas
19 March 2026
Transparency obligations for AI‑generated content under the EU AI Act: From principle to practice
12 March 2026
The UPC's first referral to the CJEU
12 March 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
25 February 2026
Trade Secrets – the strategic role of trade secrets in IP protection and how to secure and monitor trade secrets and enforce them across borders
09 February 2026
HSF Kramer contributes to Lexis Nexis Practice Note on the Protection of Geographical Indications
06 February 2026
Selling your AI digital twin - the brave new world of identity-led IP transactions: The Khaby Lame deal analysed
19 January 2026
Where is the UPC after two and a half years - and what to expect in 2026?
18 December 2025
The UPC warms to its long-arm jurisdiction powers as BSH takes effect across European patent courts
15 December 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
26 November 2025
FRAND interim licensing – where are the limits?
Showing 12 out of 277 results
View moreKey contacts
Rebekah Gay
Partner, Head of Intellectual Property, Sydney
Laura Orlando
Managing Partner, Milan Office, Milan
Sue Gilchrist
Consultant, Sydney
Peng Lei
Partner, Kewei, Mainland China and Shanghai
Alexandra Neri
Partner, Paris, Korea Group and Africa Group
Dr Ina vom Feld
Partner, Germany
Sebastian Moore
Partner, Head Intellectual Property, London and Milan
Rachel Montagnon
Knowledge Counsel, London